Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 154.05 USD -0.34%
Market Cap: 371.2B USD

JNJ's latest stock split occurred on Jun 13, 2001

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 13, 2001. This was JNJ's 6th stock split, following the previous one in Jun 12, 1996.

Last Splits:
Jun 13, 2001
2-for-1
Jun 12, 1996
2-for-1
Jun 10, 1992
2-for-1
May 11, 1989
2-for-1
May 19, 1981
3-for-1
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
Last Splits:
Jun 13, 2001
2-for-1
Jun 12, 1996
2-for-1
Jun 10, 1992
2-for-1
May 11, 1989
2-for-1
May 19, 1981
3-for-1

Johnson & Johnson
Stock Splits History

JNJ Stock Splits Timeline
Jun 13, 2001
Jun 13, 2001
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
Jun 12, 1996
Jun 12, 1996
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
Jun 10, 1992
Jun 10, 1992
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
May 11, 1989
May 11, 1989
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
May 19, 1981
May 19, 1981
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After
May 18, 1970
May 18, 1970
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
28.834
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 22, 2025
Seres Therapeutics Inc
SWB:1S9
1-for-20
/20
0.3216 6.432 EUR 6.432 6.432 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
F:4LE0
1-for-10
/10
0.011 0.11 EUR 0.11 0.11 EUR
Apr 22, 2025
E
EV Advanced Material Co Ltd
KOSDAQ:131400
911-for-787
x1.1575603557814
1493 1493 KRW 1439 1439 KRW
Apr 22, 2025
Seres Therapeutics Inc
F:1S9
1-for-20
/20
0.01 0.2 EUR 0.2 0.2 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
OTC:GSRFF
1-for-10
/10
0.024 0.24 USD 0.24 0.24 USD
Load More

Johnson & Johnson
Glance View

Economic Moat
Wide
Market Cap
370.8B USD
Industry
Pharmaceuticals

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
160.94 USD
Undervaluation 4%
Intrinsic Value
Price
Back to Top